February 2013 Vol 6, No 1, Special Issue

Initial Choice of TKI in Patients with CML Probably Not Important

Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors

Lynne Lederman, PhD

Payers' Perspectives

New Data Presented at Highlight Challenges and Opportunities for Payers

Matthew Mitchell, PharmD, MBA, FAMCP

Multiple Myeloma

Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012

Caroline Helwick

Multiple Myeloma

Four-Drug Induction and 2-Drug Maintenance Boost Overall Survival in Patients with Newly Diagnosed Myeloma

Multiple Myeloma

Host Factors Important in Patients with Myeloma

Caroline Helwick

Multiple Myeloma

New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma

Caroline Helwick

Evidence Lacking for Eliminating Prophylactic Platelet Transfusions

Bendamustine plus Rituximab Noninferior to Standard Chemotherapy for Indolent Non-Hodgkin and Mantle-Cell Lymphomas

Caroline Helwick

PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes

1
2
3

Page 1 of 3
Results 1 - 10 of 30

SUBSCRIBE

Copyright © Amplity Medical Communications. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.